Professional Summary

Professional Overview

Sarah Carter is a seasoned pharmaceutical and biotechnology executive with over 20 years of experience in clinical operations and business strategy. As the Vice President of Clinical Operations at Neumora, she oversees the company's global clinical development programs, ensuring the efficient and effective execution of critical studies.

Experience Summary

Current Role

As the Vice President of Clinical Operations at Neumora, Sarah is responsible for leading the company's clinical trial strategy, operations, and performance. She collaborates closely with cross-functional teams to drive the successful delivery of Neumora's clinical pipeline, focusing on innovative therapies for neurological and psychiatric disorders. Under her leadership, Neumora has achieved significant milestones in its clinical development programs, contributing to the advancement of treatments for patients in need.

Career Progression

Prior to joining Neumora, Sarah held various senior leadership roles at Oncovalent Therapeutics and Capsida Biotherapeutics, where she spearheaded business operations and strategic initiatives. She also served as an Executive Director at Amgen, leading global clinical program management, operations, and supplier performance management. Throughout her career, Sarah has demonstrated a proven track record of driving operational excellence, improving clinical trial efficiency, and delivering impactful results for biopharmaceutical organizations.

Academic Background

Sarah holds a Bachelor of Science degree in Pharmacy from the University of Manchester, UK, and a Master of Business Administration from the University of California, Los Angeles.

Areas of Expertise

• Clinical trial operations and program management

• Business strategy and operational optimization

• Cross-functional collaboration and team leadership

• Regulatory compliance and quality assurance

• Talent development and organizational transformation

Professional Impact

During her tenure at Amgen, Sarah led the implementation of innovative approaches to global study operations, resulting in a 25% reduction in clinical trial timelines and a significant improvement in patient recruitment and retention. At Oncovalent Therapeutics, she spearheaded the company's business operations strategy, contributing to a successful Series B funding round and the advancement of the company's oncology pipeline.

Conclusion

With her extensive experience in the pharmaceutical and biotechnology industries, Sarah Carter is a strategic and results-driven leader who is poised to drive Neumora's clinical operations to new heights. Her deep expertise in clinical development, business operations, and cross-functional collaboration positions her as a valuable asset in the pursuit of transformative therapies for patients with neurological and psychiatric conditions.